Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Purpose: Pathologic response after preoperative/neoadjuvant chemotherapy (NAC) is a continuum that can range from complete pathologic response (pCR) to extensive residual disease (RD). We hypothesized that post-NAC plasma circulating tumor DNA (ctDNA) fraction (TF) reflect pathologic response as con...
Saved in:
| Main Authors: | Naing Lin Shan, Billie Gould, Xiaohong Wang, Giancarlo Bonora, Kim Blenman, Julia Foldi, Gerson Espinoza Campos, Myles Walsh, Pan Du, Lajos Pusztai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | The Journal of Liquid Biopsy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S295019542400033X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The utilisation of ctDNA approaches for residual disease detection during neoadjuvant and perioperative immunotherapy in oesophagogastric cancers
by: Ronan J. Kelly, et al.
Published: (2025-02-01) -
Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients
by: Dong Lin, et al.
Published: (2025-07-01) -
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
by: Andrew G. Hadd, et al.
Published: (2025-03-01) -
Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More
by: Prasad Narayanan, et al.
Published: (2024-10-01) -
Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment
by: Hussein Sabit, et al.
Published: (2025-03-01)